Microfluidic Microwell Platform for Uniform Spheroid Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer drug screening models face challenges such as broad size distribution of multicellular spheroids, poorly understood metastatic niche, inadequate drug delivery under natural flow conditions, low reproducibility, and lack of throughput for evaluating drug efficacy, particularly for micrometastases which are difficult to predict and assess effectively.
Innovation Solution
A microfluidic platform for generating uniformly sized multicellular spheroids under close-to-physiological flow conditions, enabling the delivery of anticancer drugs for high-throughput screening of drug efficacy, which allows for the growth of large arrays of uniformly sized multicellular spheroids and the delivery of anticancer drugs under dynamic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional 2D culture systems are used for drug screening, then the setup is simple and cost-effective, but the models lack 3D architecture and physiological relevance, leading to poor predictive accuracy for micrometastases
Solution Approach 1:
The patent transitions from conventional 2D culture systems to 3D microfluidic spheroid models, adding a spatial dimension that replicates the architectural complexity of actual tumors. This dimensional upgrade enables more accurate prediction of drug efficacy on micrometastases while maintaining micro-scale integration.
Solution Approach 2:
The invention embeds multiple functional components within a compact microfluidic chip structure - including spheroid culture chambers, drug delivery channels, and imaging interfaces - creating a nested, integrated system that delivers complex physiological functionality without proportionally increasing external footprint or operational complexity.
2Measurement precision
If animal models are used for cancer therapy development, then physiological relevance is improved, but the studies are expensive, labor-consuming, and time-intensive with limited throughput
Solution Approach 1:
The patent creates simplified yet physiologically relevant copies of tumor microenvironments using human-derived cells cultured in 3D spheroids within microfluidic devices. These in vitro models replicate key physiological features of micrometastases without requiring whole animal systems, enabling high-throughput screening while maintaining biological relevance.
Solution Approach 2:
The invention divides the complex biological system into segmented, controllable components - isolating tumor spheroids in individual micro-wells with independent drug delivery channels. This segmentation enables parallel processing of multiple samples simultaneously, dramatically increasing screening throughput compared to sequential animal studies.
3Loss of time
If multicellular spheroids are generated by cell aggregation, then rapid formation is achieved, but broad size distribution results which interferes with drug screening efficiency
Solution Approach 1:
The patent pre-forms uniform hydrogel microbeads with controlled sizes before cell seeding. This preliminary structuring of the scaffold ensures that subsequent spheroid formation occurs within defined geometric constraints, producing uniform-sized spheroids rapidly without the size variability inherent in spontaneous cell aggregation methods.
Solution Approach 2:
The invention controls spheroid size parameters by adjusting hydrogel bead dimensions, cell density, and culture conditions. By systematically varying and optimizing these parameters, the system produces spheroids with narrow size distributions suitable for high-precision drug screening while maintaining rapid formation kinetics.
4Measurement precision
If static culture conditions are used, then the system is simple to operate, but drug delivery does not mimic natural continuous flow conditions, reducing physiological accuracy
Solution Approach 1:
The patent implements dynamic fluid flow through the microfluidic device, replacing static culture conditions with continuous medium perfusion. This dynamic system mimics natural physiological flow patterns, enhancing nutrient delivery and drug penetration while remaining operationally simple through automated pump control and standardized flow protocols.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present disclosure provides a method of producing uniformly sized organoids/multicellular spheroids using a microfluidic device having an array of microwells. The method involves several successive steps. First, a microfluidic device containing parallel rows of microwells that are connected with a supplying channel is filled with a wetting agent. The wetting agent is a liquid that is immiscible in water. For example, the wetting agent may be an organic liquid such as oil. In the next step, the agent in the supplying channel and the microwells is replaced with a suspension of cells in an aqueous solution that contains a precursor for a hydrogel. Next, the aqueous phase in the supplying channel is replaced with the agent, which leads to the formation of an array of droplets of cell suspension in the hydrogel precursor solution, which were compartmentalized in the wells. The droplets are then transformed into cell-laden hydrogels. Subsequently, the agent in the supplying channel is replaced with the cell culture medium continuously flowing through the microfluidic device and the cells within the hydrogels are transformed into multicellular spheroids.